Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.
Sorafenib: An Important Option for the Treatment of Hepatocellular Carcinoma (HCC)
Sorafenib (Nexavar) was approved in the EU and the USA for use in HCC in 2007, and remains the only systemic agent approved for use in this indication.
Jul 30,2025 APIDasatinib:Class, Uses, Advantages,Usage and Toxicity
Unlike imatinib, another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.
Jul 30,2025 APIBTK inhibitor Ibrutinib:Brand names,Uses,Dietary instructions and Toxicity
Ibrutinib is a small molecule with the ability to form a covalent bond with Cys-481 in the ATP binding domain of BTK. The IC50 of ibrutinib for BTK is 0.5 nM.
Jul 30,2025 APINilotinib: Mechanism of Action
Nilotinib shows a important role in the treatment of PVNS and GIST, this article will introduce its mechanism.
Jul 29,2025 APIUses of Regorafenib in the Treatment of Advanced Cancers
Regorafenib is an effective, orally active TKI with a mechanism of action that enables it to exhibit broad activity in various cancers.
Jul 28,2025 APICefazolin Sodium Salt: First-Generation Cephalosporin for Bone, Joint, and CNS Infections
Cefazolin sodium salt, a beta-lactam antibiotic, treats bone/joint and CNS infections via continuous infusion, showing good tolerance and efficacy.
Jul 15,2025 APIWhat Benefits does Resorcinol Cream have for the Skin?
Resorcinol is an FDA-approved over-the-counter anti-acne agent and a preservative and disinfectant in topical products that can be used to treat acne, seborrheic dermatitis, eczema, psoriasis, and oth
Jul 10,2025 APIChemical properties and Applications of Propargyl Bromide
Propargyl bromide (also known as 3-bromopropyne) is a halopropyne compound with a bromine functional group.
Jul 9,2025 APITopiramate: Anticonvulsant with Migraine Prevention and Psychiatric Applications
Topiramate treats seizures and prevents migraines by reducing brain excitability, and shows promise in psychiatric disorder treatment.
Jul 9,2025 APIEvodiamine: Bioactive Alkaloid with Anticancer, Metabolic, and Multitarget Therapeutic Potential
Evodiamine, a natural alkaloid, induces cancer cell apoptosis via mitochondrial pathways, inhibits PI3K/AKT/NF-κB in prostate cancer.
Jun 30,2025 API












